• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MAGEC2 是精原细胞瘤的一个敏感且新颖的标志物:325 例睾丸生殖细胞肿瘤的组织微阵列分析。

MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors.

机构信息

Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.

出版信息

Mod Pathol. 2011 Jun;24(6):829-35. doi: 10.1038/modpathol.2011.6.

DOI:10.1038/modpathol.2011.6
PMID:21780320
Abstract

Melanoma-associated gene C2 (MAGEC2) is a recently identified cancer testis antigen expressed in normal testicular and placental tissue. It has been detected in some human carcinomas, but its expression in primary testicular germ cell tumors is unknown. Immunohistochemistry was used to study MAGEC2 protein in 325 primary testicular germ cell tumors, including 94 mixed germ cell tumors. Seminomatous and non-seminomatous components were separately arranged and evaluated on tissue microarrays. MAGEC2 expression was compared with POU5F1 (OCT3/4), SOX2, SOX17, KIT and TNFRSF8 (CD30). The mouse monoclonal anti-MAGEC2 antibody (clone LX-CT10.5) revealed a nuclear MAGEC2 expression with little or no background staining. MAGEC2 expression was found in 238 of 254 seminomas (94%), but not in embryonal carcinomas (n=89). POU5F1 (OCT3/4) was positive in 97% of seminomas and all embryonal carcinomas. In contrast, KIT was positive in 94% of seminoma but also in 8% of embryonal carcinomas. TNFRSF8 (CD30) and SOX2 were negative in seminoma and positive in embryonal carcinoma (96 and 90%, respectively). SOX17 was positive in 94% of seminoma and negative in embryonal carcinoma. We conclude that MAGEC2 allows a reliable distinction of seminoma from embryonal carcinomas. Therefore, MAGEC2 represents an additional tool for the differential diagnosis of testicular germ cell tumors.

摘要

黑色素瘤相关基因 C2(MAGEC2)是一种新发现的癌症睾丸抗原,在正常睾丸和胎盘组织中表达。它已在一些人类癌中检测到,但在原发性睾丸生殖细胞肿瘤中的表达尚不清楚。免疫组织化学法用于研究 325 例原发性睾丸生殖细胞肿瘤中的 MAGEC2 蛋白,包括 94 例混合性生殖细胞肿瘤。在组织微阵列上分别排列和评估精原细胞瘤和非精原细胞瘤成分。比较 MAGEC2 表达与 POU5F1(OCT3/4)、SOX2、SOX17、KIT 和 TNFRSF8(CD30)。鼠单克隆抗 MAGEC2 抗体(克隆 LX-CT10.5)显示核 MAGEC2 表达,背景染色很少或没有。在 254 例精原细胞瘤中有 238 例(94%)表达 MAGEC2,但在胚胎癌中无表达(n=89)。POU5F1(OCT3/4)在 97%的精原细胞瘤和所有胚胎癌中均为阳性。相比之下,KIT 在 94%的精原细胞瘤中阳性,但在 8%的胚胎癌中阳性。TNFRSF8(CD30)和 SOX2 在精原细胞瘤和胚胎癌中均为阴性(分别为 96%和 90%)。SOX17 在 94%的精原细胞瘤中阳性,在胚胎癌中阴性。我们得出结论,MAGEC2 可可靠地区分精原细胞瘤和胚胎癌。因此,MAGEC2 是睾丸生殖细胞肿瘤鉴别诊断的另一种工具。

相似文献

1
MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors.MAGEC2 是精原细胞瘤的一个敏感且新颖的标志物:325 例睾丸生殖细胞肿瘤的组织微阵列分析。
Mod Pathol. 2011 Jun;24(6):829-35. doi: 10.1038/modpathol.2011.6.
2
D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30.D2-40免疫组织化学在精原细胞瘤和胚胎性癌鉴别诊断中的应用:与KIT(CD117)和CD30的免疫组织化学对比研究
Mod Pathol. 2007 Mar;20(3):320-5. doi: 10.1038/modpathol.3800749. Epub 2007 Feb 2.
3
Differential expression of SOX2 and SOX17 in testicular germ cell tumors.SOX2和SOX17在睾丸生殖细胞肿瘤中的差异表达。
Am J Clin Pathol. 2009 May;131(5):731-6. doi: 10.1309/AJCP7MNCNBCRN8NO.
4
Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.睾丸混合性生殖细胞肿瘤:一项使用干细胞标志物OCT3/4、SOX2和GDF3的形态学和免疫组织化学研究,重点关注形态学上难以分类的区域。
Mod Pathol. 2009 Aug;22(8):1066-74. doi: 10.1038/modpathol.2009.66. Epub 2009 Apr 24.
5
Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors - A comparative study with SOX17.在睾丸生殖细胞肿瘤中优先表达抗原黑色素瘤(PRAME)的差异表达 - SOX17 的比较研究。
Exp Mol Pathol. 2022 Jun;126:104761. doi: 10.1016/j.yexmp.2022.104761. Epub 2022 Apr 4.
6
CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma.联合使用CD30和CD117(c-kit)有助于区分胚胎癌和精原细胞瘤。
J Histochem Cytochem. 2002 Feb;50(2):283-5. doi: 10.1177/002215540205000216.
7
Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor.Wnt 抑制因子和干细胞调节因子 TCF7L1 是一种敏感的免疫组织化学标志物,可用于区分睾丸精原细胞瘤与非精原细胞瘤生殖细胞肿瘤。
Exp Mol Pathol. 2019 Oct;110:104293. doi: 10.1016/j.yexmp.2019.104293. Epub 2019 Aug 2.
8
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma.睾丸肿瘤中的OCT4染色:精原细胞瘤和胚胎性癌的敏感且特异标志物
Am J Surg Pathol. 2004 Jul;28(7):935-40. doi: 10.1097/00000478-200407000-00014.
9
Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors.胚胎干细胞转录因子特征在原发性和转移性生殖细胞肿瘤诊断中的应用
Am J Surg Pathol. 2007 Jun;31(6):836-45. doi: 10.1097/PAS.0b013e31802e708a.
10
Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers.原发性纵隔精原细胞瘤:一项以新型标志物为重点的综合免疫组织化学研究
Hum Pathol. 2015 Mar;46(3):376-83. doi: 10.1016/j.humpath.2014.11.009. Epub 2014 Nov 26.

引用本文的文献

1
Germ cell tumors in children.儿童生殖细胞肿瘤
Virchows Arch. 2025 Jan;486(1):65-79. doi: 10.1007/s00428-025-04023-7. Epub 2025 Jan 9.
2
Testicular Germ Cell Tumor Tissue Biomarker Analysis: A Comparison of Human Protein Atlas and Individual Testicular Germ Cell Tumor Component Immunohistochemistry.睾丸生殖细胞肿瘤组织生物标志物分析:人类蛋白质图谱与单个睾丸生殖细胞肿瘤成分免疫组织化学的比较。
Cells. 2023 Jul 13;12(14):1841. doi: 10.3390/cells12141841.
3
Comprehensive characteristics of pathological subtypes in testicular germ cell tumor: Gene expression, mutation and alternative splicing.
睾丸生殖细胞肿瘤病理亚型的综合特征:基因表达、突变和可变剪接。
Front Immunol. 2023 Jan 13;13:1096494. doi: 10.3389/fimmu.2022.1096494. eCollection 2022.
4
CNV Hotspots in Testicular Seminoma Tissue and Seminal Plasma.睾丸精原细胞瘤组织和精浆中的CNV热点
Cancers (Basel). 2021 Dec 31;14(1):189. doi: 10.3390/cancers14010189.
5
In Search of TGCT Biomarkers: A Comprehensive and Histopathological Analysis.探寻 TGCT 标志物:全面的组织病理学分析。
Dis Markers. 2020 Nov 6;2020:8841880. doi: 10.1155/2020/8841880. eCollection 2020.
6
The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors.维布妥昔单抗单药或联合当前临床疗法治疗睾丸生殖细胞肿瘤的潜力。
Am J Cancer Res. 2019 May 1;9(5):855-871. eCollection 2019.
7
True hermaphroditism with seminoma: A case report.真性两性畸形合并精原细胞瘤:一例报告。
Mol Clin Oncol. 2019 Jan;10(1):97-100. doi: 10.3892/mco.2018.1760. Epub 2018 Nov 8.
8
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.通过定量多重免疫组织化学和基因表达谱对睾丸癌免疫浸润及预后预测进行深入探索。
Oncoimmunology. 2017 Mar 20;6(4):e1305535. doi: 10.1080/2162402X.2017.1305535. eCollection 2017.
9
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.用于治疗非霍奇金淋巴瘤的维布妥昔单抗:一项系统评价。
Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21.
10
Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.MAGE-C2作为三阴性乳腺癌潜在生物标志物的初步研究。
Dis Markers. 2016;2016:2325987. doi: 10.1155/2016/2325987. Epub 2016 Oct 24.